Despite the limitations of a single-institution retrospective study, with risks of selection and information biases and findings that might not be generalizable to broader populations or different healthcare settings, we have reported on a large cohort of patients with NSCLC and EGFR mutations who received osimertinib treatment according to clinical practice. This evidence concerns the gene EGFR and non-small cell lung carcinoma.